A Phase 1 interventional study of Empagliflozin and Placebo in End-stage Kidney Disease, Kidney Disease, Chronic and Dialysis, sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by University of Utah · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 268th largest by enrollment of the 638 interventional ones that give a count, is one of 30 that started in 2023, is one of 89 in phase 1, and was the 679th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 30 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is close to the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 611 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 5 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients. In the recent years, empagliflozin has become a major tool to prevent heart failure hospitalization and to reduce the risk for cardiovascular death in diabetic and non-diabetic patients. Although patients with severe chronic kidney disease and ESKD have very high risk of heart failure and cardiovascular death, they have been excluded from all of the previous studies. If this medication is found to be well tolerated and safe in dialysis patients through this study, future clinical studies can evaluate if this medication can also reduce the risk of heart failure and cardiovascular death in dialysis patients.
Patients on dialysis have a very high risk of heart failure and heart-related death compared to people who do not require dialysis. While treatment options for heart failure have improved over the years for those without kidney disease, there has been very limited discoveries to improve survival for dialysis patients.
Empagliflozin, a new diabetic medication that works by making the kidney put out more sugar in the urine, has recently shown to have significant efficacy to protect the kidney and to reduce heart failure hospitalization and cardiovascular death in both diabetic and non-diabetic patients. Studies suggest that this medication may have benefits on the heart, fat cells, blood vessels, and possibly other organ systems. The benefit remains consistent whether you have diabetes or not. Empagliflozin is now approved by the U.S. Food and Drug Administration (FDA) to treat not only diabetes but also chronic kidney disease and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults regardless of the diabetes status.
The clinical studies, however, have excluded those with severe kidney disease and those requiring dialysis. The safety of empagliflozin in the dialysis patients has not been established, and thus it is not available for people with end-stage kidney disease. If empagliflozin is safe in dialysis patients, it may potentially become a very powerful tool to lower the risk of heart-related complications and prolong survival.
Although empagliflozin is approved by the FDA to treat patients with chronic kidney disease, heart failure, and/or diabetes, our study will evaluate empagliflozin as an investigational drug to assess if it is safe in patients receiving chronic dialysis. If we can establish safety, the next step would be to conduct a larger clinical study to evaluate its ability to lower heart failure and death risk in dialysis patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Empagliflozin10mg oral: Those randomized to 10 mg daily dose will be treated with 10 mg QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
Drug: Empagliflozin
Empagliflozin 25 mg oral: Those randomized to 25 mg daily dose will be treated with 10 mg QD for the first 2 weeks before escalating the dose to 25 mg QD in week 3, based on tolerability. At the end of the dose-escalation phase (weeks 3-4), participants will continue the randomized assignment for additional 8 weeks (weeks 5-12, treatment phase), for a total of 12 weeks.
Drug: Empagliflozin
Encapsulated placebo with an identical appearance to empagliflozin: Those randomized to placebo will be treated with an oral placebo QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
Other: Placebo
is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
Also known as: Jardiance®, CL-JAR-100113 02.28.2022
Placebo comparator
Study Completion
The number of participants in each intervention group who remain in follow-up and adhere to the full randomized dose of empagliflozin and placebo at the end of the 12-week intervention period.
Time frame: 12 weeks
Number of Participants in Each Group Who Reduce and/or Discontinue Treatment for Safety
Number of participants in each group who reduce and/or discontinue treatment due to safety events.
Time frame: 12-weeks
Tolerance to Study Treatment
Number of participants in each group who reduce and/or discontinue treatment because of intolerance (i.e., allergy, nausea) or other reasons unrelated to safety (i.e., pill burden, study withdrawal due to transplant)
Time frame: 12-weeks
Study Drug Compliance by Bottle Count
Number of study drug bottles returned by subjects
Time frame: 12-weeks
Dialytic Clearance of Empagliflozin
Percentage of empagliflozin removed by a 4-hour dialysis treatment
Time frame: 4 hours post-dose during hemodialysis
Long-term Accumulation of Empagliflozin
Empagliflozin plasma concentration after 10 weeks of dosing
Time frame: 10 weeks
| Milestone | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Started | 22 | 20 | 20 |
| Completed | 20 | 17 | 17 |
| Not completed | 2 | 3 | 3 |
| Milestone | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Started | 20 | 17 | 17 |
| Completed | 18 | 12 | 16 |
| Not completed | 2 | 5 | 1 |
The number of participants in each intervention group who remain in follow-up and adhere to the full randomized dose of empagliflozin and placebo at the end of the 12-week intervention period.
| Participants | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Study Completion | 18 | 12 | 16 |
Number of participants in each group who reduce and/or discontinue treatment due to safety events.
| Participants | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Number of Participants in Each Group Who Reduce and/or Discontinue Treatment for Safety | 1 | 0 | 1 |
Number of participants in each group who reduce and/or discontinue treatment because of intolerance (i.e., allergy, nausea) or other reasons unrelated to safety (i.e., pill burden, study withdrawal due to transplant)
| Participants | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Tolerance to Study Treatment | 0 | 1 | 0 |
Number of study drug bottles returned by subjects
| number of drug bottles returned | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Study Drug Compliance by Bottle Count | 71 | 62 | 70 |
Percentage of empagliflozin removed by a 4-hour dialysis treatment
| Percent of drug removed by dialysis | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Dialytic Clearance of Empagliflozin | 17.0 (15.1 to 18.9) | 7.4 (5.9 to 8.8) | — |
Empagliflozin plasma concentration after 10 weeks of dosing
| ng/mL | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Long-term Accumulation of Empagliflozin | 39.1 (10.6 to 188.0) | 55.8 (1.5 to 131.0) | — |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empagliflozin 10mg | 0/22 (0%) | 5/22 (22.7%) | 5/22 (22.7%) |
| Empagliflozin 25mg | 2/20 (10%) | 8/20 (40%) | 9/20 (45%) |
| Placebo | 0/20 (0%) | 6/20 (30%) | 7/20 (35%) |
| Event | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/22 | 1/20 | 2/20 |
| HypervolemiaCardiac disorders | 1/22 | 2/20 | 1/20 |
| Infection/SepsisInfections and infestations | 1/22 | 1/20 | 2/20 |
| Non-ST-Segment Elevation Myocardial InfarctionCardiac disorders | 1/22 | 1/20 | 0/20 |
| HypoglycemiaEndocrine disorders | 0/22 | 0/20 | 1/20 |
| Bone FractureMusculoskeletal and connective tissue disorders | 0/22 | 1/20 | 0/20 |
| EmesisGastrointestinal disorders | 0/22 | 1/20 | 0/20 |
| DepressionPsychiatric disorders | 0/22 | 1/20 | 0/20 |
| Event | Empagliflozin 10mg | Empagliflozin 25mg | Placebo |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 3/22 | 6/20 | 6/20 |
| Urinary Tract InfectionRenal and urinary disorders | 1/22 | 1/20 | 0/20 |
| ConfusionPsychiatric disorders | 0/22 | 1/20 | 1/20 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/22 | 1/20 | 0/20 |
| Age, Continuous(years) | Empagliflozin 10mg | Empagliflozin 25mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 61.6 ± 17.58 | 57.6 ± 10.18 | 55.6 ± 10.12 | 58.3 ± 13.31 |
| Sex: Female, Male(Participants) | Empagliflozin 10mg | Empagliflozin 25mg | Placebo | Total |
|---|---|---|---|---|
| Female | 6 | 6 | 8 | 20 |
| Male | 16 | 14 | 12 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Empagliflozin 10mg | Empagliflozin 25mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 8 | 9 | 21 |
| Not Hispanic or Latino | 18 | 12 | 11 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Empagliflozin 10mg | Empagliflozin 25mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 1 | 3 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 3 | 4 | 1 | 8 |
| Black or African American | 2 | 1 | 0 | 3 |
| White | 16 | 9 | 17 | 42 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 1 | 6 |
| Region of Enrollment(participants) | Empagliflozin 10mg | Empagliflozin 25mg | Placebo | Total |
|---|---|---|---|---|
| United States | 22 | 20 | 20 | 62 |
| BMI(kg/m^2) | Empagliflozin 10mg | Empagliflozin 25mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 32.2 ± 5.02 | 29.3 ± 6.04 | 32.2 ± 8.20 | 31.3 ± 6.55 |
| Type 2 diabetes(Participants) | Empagliflozin 10mg | Empagliflozin 25mg | Placebo | Total |
|---|---|---|---|---|
| Count of participants | 14 | 15 | 14 | 43 |
| Heart failure(Participants) | Empagliflozin 10mg | Empagliflozin 25mg | Placebo | Total |
|---|---|---|---|---|
| Count of participants | 11 | 8 | 5 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2023 to primary completion in Jun 2025, 27 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
Of 67 phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 27 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin